Linoleic Acid and Cancer Growth: What a 2025 Study Really Found

By Editorial Team

A New Mechanism Links Dietary Fat to Aggressive Breast Cancer — With Important Caveats

Researchers at Weill Cornell Medicine have identified a specific biological mechanism through which omega-6 linoleic acid — a fatty acid common in Western diets — may promote the growth of an aggressive form of breast cancer. The study, published in the journal Science, is being widely discussed online, but the findings are more precise — and more limited — than many headlines suggest.

Here is a clear-eyed breakdown of what the research found, what it means for different people, and what questions remain unanswered.

What Is Linoleic Acid?

Linoleic acid (LA) is an omega-6 polyunsaturated fatty acid and an essential nutrient — meaning the human body cannot produce it on its own and must obtain it through food. It is found in:

  • Vegetable and seed oils (sunflower, soybean, safflower, corn)
  • Nuts and seeds
  • Poultry and eggs
  • Many packaged and processed foods
Omega-6 fatty acids, including LA, play important roles in cell membrane structure, immune function, and inflammation regulation. The scientific consensus holds that LA is beneficial at normal dietary levels, though debates exist about the effects of high intake in the context of modern Western diets.

What the Study Found

The Weill Cornell study, published in Science (1), investigated how linoleic acid interacts with triple-negative breast cancer (TNBC) — one of the most aggressive and treatment-resistant forms of breast cancer, which lacks estrogen, progesterone, and HER2 receptors.

The Key Mechanism: FABP5 and mTORC1

The researchers discovered a two-step process:

  1. FABP5 acts as a transporter. Fatty acid binding protein 5 (FABP5) — a protein found at elevated levels in TNBC tumors — picks up linoleic acid and shuttles it into cancer cells.
  2. mTORC1 is activated. Once inside, linoleic acid triggers mTORC1 (mechanistic target of rapamycin complex 1), a well-known cellular growth switch that signals cells to divide and multiply.

In animal models, mice with TNBC that were fed a high-LA diet developed larger, faster-growing tumors compared to mice on a lower-LA diet. The effect was tied directly to FABP5 expression: tumors with higher FABP5 levels showed stronger responses to dietary LA.

"This discovery helps clarify the relationship between dietary fats and cancer, and sheds light on how to define which patients might benefit the most from specific nutritional recommendations in a personalized manner."
— John Blenis, PhD, Senior Author, Weill Cornell Medicine

Why This Research Matters

This study is scientifically significant for several reasons:

  • It is the first to identify a specific molecular mechanism linking dietary omega-6 linoleic acid to cancer cell growth — previous research had produced mixed or inconclusive results.
  • It points toward FABP5 as a potential biomarker — patients whose tumors express high FABP5 may one day receive personalized dietary or therapeutic recommendations.
  • The mTORC1 pathway is already a major target in cancer drug research, so this connection opens additional avenues for treatment development.

Co-author Nikos Koundouros, PhD, noted there may be "a broader role for FABP5-mTORC1 signaling in other cancer types and even in common chronic diseases such as obesity and diabetes" — though this remains speculative and requires further study.

What the Study Does NOT Mean

This is where accurate reporting matters most. Several things this study does not show:

1. It does not prove LA causes cancer in humans

The research was conducted in animal models and cell cultures. Translating animal study results to human dietary recommendations requires large, long-term clinical trials — none of which yet exist for this specific mechanism.

2. It does not apply to all cancers — or all people

The FABP5-mTORC1 pathway was identified specifically in triple-negative breast cancer, which has unusually high FABP5 expression. Other cancer types — and healthy cells — respond very differently to linoleic acid. In fact, separate research has found LA exhibits anti-proliferative effects in endometrial cancer, and its effects in colorectal cancer appear dose-dependent.

3. Large population studies show no increased overall cancer risk from LA

Multiple large human cohort studies have found no significant association between typical dietary linoleic acid intake and increased overall cancer risk. Some studies have found inverse associations — meaning higher LA intake correlates with lower incidence of certain cancers.

4. Linoleic acid is an essential nutrient, not a toxin

The body requires LA for normal function. Recommending intake below 5 grams per day — far below typical needs — is not supported by current nutritional science and could create deficiencies affecting skin health, hormone production, and immune function.

What This Means for Diet and Cancer Prevention

Based on the totality of current evidence, here is what is reasonable to conclude:

For the general population:
There is no strong evidence that reducing linoleic acid below normal levels reduces cancer risk. Standard dietary guidance — eating a varied, whole-food diet, limiting ultra-processed foods, maintaining a healthy weight, and avoiding smoking — remains the best-supported approach to cancer risk reduction.

For TNBC patients and high-risk individuals:
This research suggests that FABP5 expression levels may one day inform personalized dietary guidance for TNBC patients. Oncologists and registered dietitians are the right source of advice here — not general population dietary rules.

What the evidence does support:
Reducing ultra-processed food consumption is associated with improved health outcomes across multiple disease categories. Many processed foods are high in LA and refined carbohydrates, added sugars, and sodium — all of which have independent health implications.

Frequently Asked Questions

Q: Should I stop eating seed oils because of this study?
A: No — not based on this study alone. The research identified a mechanism in a specific cancer type using animal models. Broad dietary changes for the general public are not supported by this evidence.

Q: Is linoleic acid bad for you?
A: At normal dietary levels, no. LA is an essential fatty acid. The concern in this study is about a specific mechanism in a specific cancer type (TNBC), particularly in people whose tumors express high levels of FABP5.

Q: What is FABP5 and should I get tested for it?
A: FABP5 is a protein found at elevated levels in some aggressive cancers, particularly TNBC. It is not currently a standard clinical test, but it may become a useful biomarker as this research develops.

Q: What dietary fats are safest?
A: Current evidence supports a diet rich in a variety of fats — including monounsaturated fats (olive oil, avocado), omega-3 fatty acids (fatty fish, flaxseed), and modest amounts of saturated and polyunsaturated fats. Extreme restriction of any single fat type is generally unnecessary for healthy individuals.

Q: Will reducing linoleic acid cure or prevent cancer?
A: No evidence currently supports this claim. If you have been diagnosed with cancer, work with your oncologist and a registered dietitian for evidence-based nutritional guidance.

The Bottom Line

The Weill Cornell Science study is a meaningful scientific contribution. It identifies, for the first time, a specific pathway through which dietary linoleic acid may accelerate triple-negative breast cancer growth in animal models — and points toward FABP5 as a potential therapeutic and dietary target for a subset of cancer patients.

What it does not do is justify sweeping dietary restrictions for healthy people, nor does it overturn decades of nutritional research establishing linoleic acid as an essential and generally beneficial nutrient.

As with most early-stage mechanistic research, the right response is continued investigation — not alarm. Future clinical trials examining FABP5 expression and dietary fat in TNBC patients will be the necessary next step before any firm recommendations can be made.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet or health regimen.

Sources:

  1. Koundouros N, et al. Science, 2025. DOI: 10.1126/science.adm9805
  2. Weill Cornell Medicine press release, April 1, 2025
  3. Qiu J, et al. Cancer Biology & Therapy, 2024. DOI: 10.1080/15384047.2024.2325130
  4. Johnson GH, Fritsche K. Journal of the Academy of Nutrition and Dietetics, 2012

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more